Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
- Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors
- Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer
- Financing supports Ona’s transition to a clinical-stage company and delivery of key clinical and regulatory milestones
Barcelona, Spain, 4 June 2026: Ona Therapeutics (“Ona”), a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, today announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV and Ysios Capital.
